Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma stock last closed at $33.70, up 0.6% from the previous day, and has increased 10.75% in one year. It has overperformed other stocks in the Biotechnology industry by 0.92 percentage points. Royalty Pharma stock is currently +40.12% from its 52-week low of $24.05, and -1.46% from its 52-week high of $34.20.
As of Mar 21, 2025, there are 576.45M RPRX shares outstanding. The market capitalization of RPRX is $19.43B. In the past 24 hours, 6.92M RPRX shares were traded.
How to Buy Royalty Pharma Stock
Not sure how to invest in Royalty Pharma stock? Here's how.
Decide where to buy Royalty Pharma stock: You need to choose an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Royalty Pharma stock.
Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit money your investment account: Choose your payment method and add your details.
Analyze Royalty Pharma stock: The Royalty Pharma ticker symbol is RPRX. Is Royalty Pharma stock a good investment? Should you buy shares of RPRX? How do RPRX's underlying business fundamentals look? Do top analysts think Royalty Pharma is a good buy? Why has RPRX's stock price moved recently? (Hint: Our stock research tools can help you understand if RPRX is a good stock to buy).
Execute your RPRX purchase: Decide if you will purchase RPRX shares at the current market price or use a limit order to purchase RPRX stock at a given price.
Keep tabs on your RPRX position: Create a watchlist to get the latest news on your new investment in Royalty Pharma stock.
Step 1: Decide where to buy Royalty Pharma stock
You will need a brokerage account in order to access the NASDAQ market and buy RPRX shares.
A brokerage account is an investment account that allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world financial markets: From Tech to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal information so you are able to buy RPRX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Royalty Pharma stock
After you have identified the best place to buy Royalty Pharma stock, it's critical to research their stock before you buy, so you truly understand the risk as well as the upside.
Overview of key RPRX info
RPRX Price
$33.70
1w %
2.84%
1y %
10.75%
5y %
N/A
P/E
17.55x
P/B
1.88x
P/S
6.67x
PEG
0.31x
Revenue
$2.26B
Earnings
$858.98M
Fore. Rev. Growth
19.38%
Fore. Earn. Growth
62.05%
Market Cap
$19.43B
Next Earnings
May 7, 2025
Next Dividend
N/A
Royalty Pharma Overview
WallStreetZen was designed to help everyday investors do better fundamental analysis in less time.
Last year, RPRX earnings were $858.98M. In the past 4 year, RPRX's earnings have grown by 9.82% per year. This was slower than the Biotechnology industry average of 11.3%.
Last year, RPRX revenue was $2.26B. Over the past 5 year, RPRX's revenue has gone up by 4.52% per year. This was slower than the Biotechnology industry average of 45.96%.
Royalty Pharma pays a dividend of 1.28%, compared to the Biotechnology industry's average dividend yield of 1.73%. If you owned $1,000 of RPRX stock, you would have been paid $12.76 in the past 12 months.
Royalty Pharma dividend payments have consistently grown over the past 5 years and have remained stable.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your RPRX purchase
You have two primary options:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are usually the easiest way to buy.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a particular dollar amount, use a limit order.
Press the Open button and eToro will place the order.
If you want additional help buying stocks on eToro, click the how to video below:
How much does it cost to buy one Royalty Pharma share?
As of Mar 21, 2025, it costs $33.70 to buy one share of Royalty Pharma stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.297 shares of RPRX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.